Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04227899 · ClinicalTrials.gov registry record · NA
LIFE-BTK Randomized Controlled Trial
A NA study of Critical Limb Ischemia (CLI), sponsored by Abbott Medical Devices.
- Active
- Registry status
- NA
- Development phase
- 261
- Enrollment target
- 20
- Study locations
NCT04227899 is a NA study of Critical Limb Ischemia (CLI) that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 261 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT04227899, a NA study of Critical Limb Ischemia (CLI), is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 261 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everolimus eluting Esprit BTK System for the planned treatment of narrowed infrapopliteal lesions. Approximately 225 subjects will be randomized in a 2:1 ratio. The clinical investigation will be conducted at approximately 65 clinical sites in the US, Asia, Australia, and New Zealand.
Conditions Studied
Interventions
- DEVICE Percutaneous Transluminal Angioplasty (PTA) Device
- DEVICE Esprit BTK Device
Study Locations (20)
California
- St. Helena Hospital - Deer Park
- Mission Cardiovascular Research Institute - Fremont
- UCSF Fresno - Fresno
- St. Joseph Hospital - Orange
Florida
- Manatee Memorial Hospital - Bradenton
- First Coast Cardiovascular Institute - Jacksonville
- Palm Vascular Centers - Miami Beach
- Tallahassee Research Institute - Tallahassee
Massachusetts
- St. Elizabeth's Medical Center - Boston
- Charlton Memorial Hospital - Russells Mills
Arizona
- Comprehensive Integrated Care - Gilbert
Arkansas
- Arkansas Heart Hospital - Little Rock
Colorado
- University of Colorado Hospital - Aurora
Connecticut
- Yale New Haven Hospital - New Haven
Georgia
- Piedmont Heart Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2027-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04227899
The ClinicalTrials.gov registry entry for NCT04227899 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Critical Limb Ischemia (CLI) appearing as the primary indexed condition, and to 2 interventions - of which Percutaneous Transluminal Angioplasty (PTA) Device is the first listed.
NCT04227899 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04227899 about?
NCT04227899 is a clinical study titled "LIFE-BTK Randomized Controlled Trial". The objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everolimus eluting Esprit BTK System for the planned treatment of narrowed infrapopliteal lesions. Approximately 225 subjects will be randomized in a 2:1 rati...
What is the current status of trial NCT04227899?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 261 participants. The study started on 2020-08-18. Estimated completion is 2027-07.
What conditions does trial NCT04227899 study?
This clinical trial studies the following conditions: Critical Limb Ischemia (CLI).
What interventions are being tested in trial NCT04227899?
The interventions under investigation include: Percutaneous Transluminal Angioplasty (PTA) Device (DEVICE), Esprit BTK Device (DEVICE).
Who is sponsoring clinical trial NCT04227899?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04227899 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Critical Limb Ischemia (CLI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.